SVRA

Savara Inc. 10-K Filing Summary

Business Context and Reporting Period

Company: Savara Inc. (SVRA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole product candidate is MOLBREEVI (molgramostim inhalation solution), an investigational inhaled biologic for the treatment of autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company has no commercial product revenue and relies on capital markets and debt financing to fund operations.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The company reported no revenue. Operating expenses increased primarily due to regulatory affairs costs related to the Biologics License Application (BLA) and expanded general and administrative costs.

Material Changes vs. Prior Period

• Regulatory Milestone: In May 2025, the FDA issued a Refusal to File (RTF) for the initial BLA submission. Savara resubmitted the BLA in December 2025. In February 2026 (subsequent to period end), the FDA formally filed the BLA and granted Priority Review.
• Capital Raising: In October 2025, the company completed an underwritten public offering raising approximately $140.2 million in net proceeds.
• Debt Restructuring: In March 2025, Savara entered a new loan agreement with Hercules Capital, borrowing $30 million to repay prior Silicon Valley Bank debt. In January 2026, the agreement was amended to allow for up to $75 million in additional term loans contingent on FDA approval.
• Royalty Monetization: In October 2025, Savara entered a purchase agreement with RTW Investments, LP to sell a portion of future U.S. royalties for a potential $75.0 million payment upon FDA approval (subject to closing conditions).
• Expense Growth: General and Administrative expenses rose 68% year-over-year to $42.1 million, driven by workforce expansion and commercial preparation activities.

Guidance, Outlook, and Risks

Outlook: Management expects to continue incurring significant operating losses as it advances MOLBREEVI toward commercialization. The company believes its current liquidity ($235.7 million) is sufficient to fund operations for at least the next 12 months. Future funding requirements depend on the pace of regulatory approval and commercial launch.

Key Risks:

• Regulatory Approval: The business is entirely dependent on the approval of MOLBREEVI. While Priority Review was granted, approval is not guaranteed.
• Manufacturing Dependence: Savara relies entirely on third-party contract manufacturers (Fujifilm for drug substance, Patheon for drug product, PARI for nebulizers). Supply chain disruptions or quality issues could delay approval or commercialization.
• Debt Covenants: The Hercules Loan Agreement contains restrictive covenants, including a "Cash Requirement" (maintaining cash equal to 50-70% of outstanding debt) and a "Conditional Minimum Revenue Covenant" post-approval. Failure to comply could trigger immediate repayment.
• Competition: Sargramostim (Leukine) was approved in Japan for autoimmune PAP in April 2024, presenting a competitive threat in that market.

Investor Verification Checklist

• BLA Status: Confirm the FDA's final decision on the Priority Review application filed in February 2026.
• Debt Covenants: Verify compliance with the Hercules Loan Agreement's cash maintenance covenants, particularly the requirement to hold 50% of debt principal in cash.
• Royalty Agreement Closing: Monitor the conditions precedent for the $75 million royalty sale to RTW Investments, specifically the FDA approval deadline of March 31, 2027.
• Manufacturing Validation: Review updates on the technology transfer from GEMA to Fujifilm and the comparability data required for commercial supply.
• Liquidity Runway: Assess burn rate relative to the $235.7 million cash position to determine if additional equity or debt financing will be required before commercial revenue begins.